Ana De Jesus is an Oncologist in Baltimore, Maryland. Dr. De Jesus is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. Her top areas of expertise are Pancreatic Cancer, Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Jin He, M.D., Ph.D., is a professor of surgery at the Johns Hopkins University School of Medicine and is the Division Chief of Hepato-Pancreato-Biliary & Gastrointestinal Surgical Oncology. Dr. He specializes in diseases and tumors of the pancreas, liver, bile duct, and gallbladder. He performs open as well as minimally invasive (robotic and laparoscopic) surgery, including the Whipple procedure. Dr. He received his medical degree from Beijing Medical University and a Ph.D. in oncology from Fudan University Shanghai Medical College. He completed the Halsted general surgery residency training at Johns Hopkins, followed by an ACGME accredited fellowship in complex general surgical oncology at Johns Hopkins. Dr. He is the John Cameron Professor of Alimentary Tract Diseases. Dr. He’s research focuses on personalized treatment through stratifying pancreatic tumors on their genetic features. He holds several patents in anti-cancer vascular targeting agents and has published extensively in peer-reviewed journals and lectured internationally. He serves on several national committees, including the NCCN panel on neuroendocrine tumors and the Alliance for Clinical Trials in Oncology. Dr. He is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. His top areas of expertise are Pancreatic Cancer, Neuroendocrine Tumor, Cholangiocarcinoma (Bile Duct Cancer), Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Cameron has had a long and distinguished career in alimentary tract diseases and specifically in pancreatic cancer. He has won worldwide acclaim for mastering the Whipple procedure. At the beginning of his career, the mortality rate from the Whipple procedure was nearly 30 percent. He has worked to lower that to 1 percent to 2 percent at Johns Hopkins. He has operated on more patients with pancreatic cancer and done more Whipple resections than any other surgeon in the world. In addition to maintaining a busy practice that focuses mainly on pancreatic surgery, he has been a leader in the surgical profession, serving as president of the American College of Surgeons, Society for Surgery of the Alimentary Tract, Southern Surgical Association, Society of Clinical Surgery, Society of Surgical Chairmen, Halsted Society and American Surgical Association. He served as chief of surgery for The Johns Hopkins Hospital for nineteen years. Dr. Cameron obtained his undergraduate degree from Harvard University in 1958, and his medical degree from The Johns Hopkins University School of Medicine in 1962. All of his training in General and Thoracic Surgery was obtained at The Johns Hopkins Hospital. Dr. Cameron is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Islet Cell Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Daniel Laheru is a cancer specialist in Baltimore, caring for patients with pancreatic cancer, colorectal cancer and neuroendocrine cancers. Dr. Laheru serves as co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care at Johns Hopkins Medicine. Dr. Laheru received his undergraduate degree in chemistry from The University of Utah. He earned his M.D. at Baylor College of Medicine. He completed his residency at The University of Utah Hospital and Clinics and performed a fellowship in medical oncology at The Johns Hopkins University School of Medicine and The Johns Hopkins Oncology Center. Dr. Laheru joined the Johns Hopkins faculty in 2001. Dr. Laheru's research interests include pancreatic cancer and chemotherapy resistance in pancreatic cancer. With Elizabeth Jaffee, M.D., he developed a vaccine that supercharges the immune system and causes immune cells, which tend to be tolerant of cancer, to seek out and kill pancreatic cancer cells throughout the body. He has given numerous invited talks on pancreatic cancer and other cancers both nationally and internationally. He has authored over 200 papers focused on pancreatic cancer. Dr. Laheru serves as associate editor of Annals of Pancreatic Cancer. He has been recognized by the American Society of Clinical Oncology with the Young Investigator Award, by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as an Isaac and Catharine Hecht Scholar and has been elected to the Miller-Coulson Academy of Clinical Excellence. He is a member of the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Laheru is rated as an Advanced provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Nilofer S. Azad is Professor of Oncology at Johns Hopkins University School of Medicine and serves as the Associate Cancer Center Director for Clinical Research for the Johns Hopkins Sidney Kimmel Cancer Center. Dr. Azad earned her medical degree and completed a residency in internal medicine at Baylor College of Medicine in Houston, Texas. She then completed a fellowship in oncology and hematology at the National Institute of Health's National Cancer Institute in Bethesda, Maryland where she served as chief fellow. Dr. Azad’s research focused on early phase drug development and the intersection of moving exciting laboratory findings into patients for new treatment options Dr. Azad joined the faculty at the Kimmel Cancer Center in 2008. Dr. Azad’s clinical expertise is in cancers of the gastrointestinal tract, with a concentration in colorectal cancer, cholangiocarcinoma and pancreaticobiliary tract cancer. Her research efforts are dedicated to developing new drug combinations for patients with advanced cancer. In particular, Dr. Azad’s laboratory and clinical trials explore epigenetic therapy in combination with chemotherapy and immunotherapy to improve survival for patients, as well as molecularly targeted drugs. She is an active clinical trialist, leading multiple clinical trials of molecularly targeted agents for advanced cancer patients. Dr. Azad has received numerous grants for her work from entities such as the NCI (National Cancer Center), American Cancer Society, American Society of Clinical Research, Breakthrough Cancer Foundation, the Lustgarten Foundation, The Gateway Foundation, and the National Comprehensive Cancer Network, among others. She served as Principal for Johns Hopkins on the AACR Stand Up 2 Cancer Colorectal Cancer Dream Team and is a member of the Stand Up 2 Cancer Epigenetics Dream Team, leading the GI cancer initiatives for the group. Dr. Azad is a national leader in GI cancer, including serving as a member of the national NCI Colon Cancer Task Force and as Co-Chair of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. She has a presidential appointment to the National Cancer Advisory Board. Dr. Azad is rated as an Advanced provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. Her top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Pancreatic Cancer, Hepato-Pancreato-Biliary Surgery, and Liver Embolization.

Richard Burkhart, M.D., is an Associate Professor of Surgery at The Johns Hopkins Hospital with a focus on complex minimally-invasive surgery and research for cancers of the pancreas, liver and bile ducts. Dr. Burkhart received his medical degree from Boston University and completed his surgical residency and research fellowships at the Thomas Jefferson University Hospital in Philadelphia and the Cold Spring Harbor Laboratories. He is a member of several professional organizations, including the American Association of Cancer Research, the American College of Surgeons, the Society of Surgery for the Alimentary Tract, the Pancreas Club, and the Society of Surgical Oncology. Outside the operating room, Dr. Burkhart heads a multidisciplinary laboratory team dedicated to bringing next-generation precision medicine approaches into the routine clinical care of patients that we serve. He has a particular research interest in using personalized models of pancreas cancer, made from tumor during and immediately after surgical resection, to select the best chemotherapy for each patient to support long-term survival and improve rates of disease cure. The laboratory team, funded in part by the National Institutes of Health, the National Cancer Institute, the Lustgarten Foundation and Stand Up to Cancer, is also thankful to the many patients who have supported the work through philanthropic gift. Dr. Burkhart is rated as an Advanced provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, Pancreatectomy, and Pancreaticoduodenectomy.

Debashish Bose is a Surgical Oncologist and a General Surgeon in Baltimore, Maryland. Dr. Bose is rated as an Experienced provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. His top areas of expertise are Pancreatic Pseudocyst, Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatectomy, and Small Bowel Resection. Dr. Bose is currently accepting new patients.

Kelly Lafaro, MD, MPH, is a general surgeon with a specialty in gastrointestinal surgical oncology and hepatobiliary surgery. She is part of the Johns Hopkins Kimmel Cancer Center. Dr. Lafaro earned her medical degree from Tulane University School of Medicine and completed her residency at New York-Presbyterian/Columbia University Irving Medical Center. Her fellowship in complex general surgical oncology was completed at City of Hope National Medical Center. Dr. Lafaro’s expertise includes pancreatic adenocarcinoma, neuroendocrine tumors, minimally invasive pancreatic and liver surgeries, and colorectal liver metastases. In addition to her clinical experience, Dr. Lafaro is published in the field of liver and pancreatic cancer. She is interested in the improvement of surgical and post-surgical outcomes. Dr. Lafaro is rated as an Experienced provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. Her top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Neuroendocrine Tumor, Pancreatectomy, and Pancreaticoduodenectomy.

Dung Le, M.D. is a professor of oncology at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center. Her research interests include novel approaches to patients with gastrointestinal malignancies. She has served as the principal investigator (PI) on many clinical trials focused on testing immunotherapy in patients with gastrointestinal malignancies and she has also served as the national PI on several studies including: anti-programmed death-1 (PD-1) in tumors with mismatch repair deficiency; a clinical trial in advanced pancreatic cancer patients evaluating the safety, tolerability and immune response to CRS-207, a listeria vaccine platform which has been modified to express the tumor antigen mesothelin; a multi-center, phase 2 study testing CRS-207 as a boost to allogenic pancreatic tumor cells transfected with GM-CSF gene (GVAX) for treatment of advanced pancreatic adenocarcinoma (PDA); a trial testing GVAX/ipilimumab in the maintenance setting for metastatic pancreatic cancer; and GVAX/CRS-207 +/- nivolumab in metastatic pancreatic cancer. These studies incorporate extensive laboratory correlates and have involved collaborations with clinicians and bench scientists with expertise in the fields of immunotherapy and cancer genomics. Dr. Le is rated as an Experienced provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. Her top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Gastroesophageal Junction Cancer, and Familial Pancreatic Cancer.

Christopher Shubert, M.D., M.H.A., is a general surgeon with specialty training and interests in hepato-pancreato-biliary (HPB) surgery. He is a member of the Division of Hepato-Pancreato-Biliary & Gastrointestinal Surgical Oncology at The Johns Hopkins Hospital. Dr. Shubert earned his medical degree from the University of Alabama School of Medicine and completed his general surgery residency at the Mayo Clinic in Rochester, Minnesota. He completed fellowship training in HPB surgical oncology and abdominal organ transplantation at the University of Toronto. In addition to his clinical experience, Dr. Shubert earned a Master's of Science in Healthcare Administration from the University of Alabama at Birmingham. Dr. Shubert's clinical interests include HPB surgery, resection of traditionally unresectable liver lesions, tumors involving the vena cava, and pancreas resections with vascular reconstruction. His research focus includes hepatobiliary and pancreatic malignancies, their respective treatments, perioperative management, and outcomes. Dr. Shubert is rated as an Experienced provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. His top areas of expertise are Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Ductal Adenocarcinoma, Pancreaticoduodenectomy, and Pancreatectomy.

Marina Baretti, MD, is an assistant professor at Johns Hopkins University School of Medicine and the Jiasheng Chair in Hepato-Biliary Cancer Research. She also serves as Co-Director of the Liver and Biliary Cancer Multidisciplinary Clinic at the Sidney Kimmel Comprehensive Cancer Center (SKCCC). Dr. Baretti received her medical degree from the University of Pisa in Italy. She completed her internal medicine residency and oncology fellowship at University of Milan. She then went on and completed her Postdoctoral and Medical Oncology Fellowship at Johns Hopkins University, Baltimore, Maryland. She is deeply engaged in bridging the gap between laboratory discoveries and clinical application, working closely with laboratory-based scientists to accelerate the development of novel therapeutic strategies. Her academic research is centered on the development of novel agents in hepatobiliary cancers, with particular interest in combinatorial approaches of immunotherapies. She is currently the principal investigator on multiple clinical trials in FLC, HCC and cholangiocarcinoma at Johns Hopkins University, collaborating closely with laboratory-based researchers to move laboratory findings into patients. Through her work, Dr. Baretti strives to improve outcomes for patients with rare GI cancers by identifying innovative therapies that are informed by a deeper understanding of tumor biology and the tumor microenvironment. Dr. Baretti was the recipient of the 2018 American Society of Clinical Oncology Young Investigator Award. Dr. Baretti was also awarded with the 2020 Career Development Award for the MD Anderson Cancer Center’s pancreatic cancer NCI Specialized Programs of Research Excellence (SPORE). Dr. Baretti is rated as an Experienced provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. Her top areas of expertise are Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, and Pancreatic Cancer.

Gastroenterologist Mouen Khashab specializes in therapeutic endoscopy, and he oversees this group of practitioners across the Johns Hopkins enterprise. Nationally and internationally known in the field of interventional endoscopy, Dr. Khashab has contributed immensely to the field’s advancement as a minimally invasive means to treat gastrointestinal and pancreaticobiliary disorders. Dr. Khashab earned his medical degree from the American University of Beirut Faculty of Medicine, and subsequently completed a residency in internal medicine and a fellowship in gastroenterology at Indiana University. He then completed a two-year fellowship at The Johns Hopkins Hospital before joining the faculty in 2011. A busy researcher, Dr. Khashab has published more than 600 papers in peer-reviewed journals. In 2013, he described the procedure called gastric peroral endoscopic myotomy (known as G-POEM) and was able to disseminate and teach it all over the world. Other procedures that he expanded include peroral endoscopic myotomy (POEM), peroral endoscopic myotomy with fundoplication (POEM-F), Zenker’s peroral endoscopic myotomy (Z-POEM) and full thickness resection. In 2022, he received the Master Endoscopist Award from the American Society for Gastrointestinal Endoscopy (ASGE) for his numerous contributions to the field. His procedural expertise includes endoscopic retrograde cholangiopancreatography (ERCP), endoscopic ultrasound (EUS), interventional EUS, submucosal endoscopy, POEM/achalasia, endoscopic mucosal resection, endoscopic submucosal dissection, luminal stenting, large polyp resection and Barrett’s therapy, among others. Dr. Khashab is involved with multiple gastrointestinal societies and has served on many committees, including the ASGE Standards of Practice Committee, which is in charge of formulating guidelines for the practice of endoscopy. He has also served as an associate editor for the journal Endoscopy, a premier journal in the field. Khashab is a highly sought-after speaker at national and international conferences, and he has participated in multiple live endoscopy conferences. Outside of academic medicine, Dr. Khashab is an entrepreneur. His major interest is in new technology and medical devices, and his goal is to disrupt the field by introducing technology that makes endoscopic procedures safer, easier, efficient and more scalable. Dr. Khashab is rated as an Experienced provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. His top areas of expertise are Achalasia, Pancreatic Pseudocyst, Bile Duct Obstruction, Endoscopy, and Gastric Bypass.

Petr Hausner is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Hausner is rated as an Experienced provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. His top areas of expertise are Pseudomyxoma Peritonei, Colorectal Cancer, Familial Colorectal Cancer, and Anal Cancer. Dr. Hausner is currently accepting new patients.

Marvin Feldman is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Feldman is rated as an Experienced provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. His top areas of expertise are Anal Cancer, Laryngeal Cancer, Familial Colorectal Cancer, and Angiosarcoma.

Yixing Jiang is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Jiang is rated as an Experienced provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. Her top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Familial Pancreatic Cancer, Anal Cancer, and Gastrostomy. Dr. Jiang is currently accepting new patients.

Andrea Speedie is a primary care provider, practicing in Family Medicine in Baltimore, Maryland. Dr. Speedie is rated as an Experienced provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. Her top areas of expertise are Myelitis, AIDS Dysmorphic Syndrome, HIV/AIDS, and AIDS Dementia Complex. Dr. Speedie is currently accepting new patients.

Nephtali Gomez is a General Surgeon in Baltimore, Maryland. Dr. Gomez is rated as an Experienced provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. His top areas of expertise are Pancreatic Pseudocyst, Pancreatic Cancer, Familial Pancreatic Cancer, Pancreaticoduodenectomy, and Pancreatectomy.

Martin Makary is a General Surgeon in Baltimore, Maryland. Dr. Makary is rated as an Experienced provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. His top areas of expertise are Chronic Pancreatitis, Pancreatic Cancer, Hereditary Pancreatitis, Pancreatectomy, and Pancreaticoduodenectomy. Dr. Makary is currently accepting new patients.

Brian Ramnaraign is a Hematologist Oncology specialist and a Geriatrics provider in Baltimore, Maryland. Dr. Ramnaraign is rated as an Experienced provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Familial Pancreatic Cancer, and Familial Colorectal Cancer. Dr. Ramnaraign is currently accepting new patients.

Syed Nasir is a Hematologist and an Oncologist in Towson, Maryland. Dr. Nasir is rated as an Experienced provider by MediFind in the treatment of Pancreatic Islet Cell Tumor. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Paget Disease of the Breast.